Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, Pirmohamed M,
Park BK. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to
toxicity and major histocompatibility complex-restricted antigen presentation. Mol
Pharmacol 2002;62:628–637.
Nassar AE, Bjorge SM, Lee DY. On-line liquid chromatography-accurate radioisotope
counting coupled with a radioactivity detector and mass spectrometer for metabolite
identification in drug discovery and development. Anal Chem 2003;75:785–790.
Nassar AE, Parmentier Y, Martinet M, Lee DY. Liquid chromatography-accurate
radioisotope counting and microplate scintillation counter technologies in drug
metabolism studies. J Chromatogr Sci 2004;42:348–353.
Obach RS. Nonspecific binding to microsomes: impact on scale-up ofin vitrointrinsic
clearance to hepatic clearance as assessed through examination of warfarin,
imipramine, and propranolol. Drug Metab Dispos 1997;25:1359–1369.
Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic
microsomal intrinsic clearance data: an examination ofin vitrohalf-life approach
and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350–1359.
Obach RS. The prediction of human clearance from hepatic microsomal metabolism
data. Curr Opin Drug Discov Devel 2001;4:36–44.
Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ,
Wastall P. The prediction of human pharmacokinetic parameters from preclinical
andin vitrometabolism data. J Pharmacol Exp Ther 1997;283:46–58.
Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of
metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol
2005;45:177–202.
Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An
investigation of the formation of cytotoxic, protein-reactive and stable metabolites
from carbamazepinein vitro. Biochem Pharmacol 1992;43:1675–1682.
Rane A, Wilkinson GR, Shand DG. Prediction of hepatic extraction ratio fromin vitro
measurement of intrinsic clearance. J Pharmacol Exp Ther 1997;200:420–424.
Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T Jr,Lin
LS, Hagmann WK, Evans DC, Kumar S. Addressing the metabolic activation
potential of new leads in drug discovery: a case study using ion-trap mass
spectrometry and tritium labeling techniques. J Mass Spectrom 2003;38:211–221.
Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-
Hodjegan A. Prediction of metabolic drug clearance in humans:in vitro–in vivo
extrapolation vs allometric scaling. Xenobiotica 2006;36:567–580.
Shu YZ, Li W, Leet JE, Alberts J, Arora VK, Yeola S, Philip T, Qian-Cutrone J, Zhao
N, Santone K, Humphreys WG, Dickinson K. Biogram enabled evaluation of active
metabolites: an exploratory approach for detecting and characterizing active/toxic
drug metabolites. Drug Metab Rev 2002;34 (1 Suppl):75.
Singh R, Silva Elipe MV, Pearson PG, Arison BH, Wong BK, White R, Yu X, Burgey
CS, Lin JH, Baillie TA. Metabolic activation of a pyrazinone-containing thrombin
inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation,
rearrangement, and covalent binding to proteins. Chem Res Toxicol 2003;16:
198–207.
258 DRUG METABOLISM RESEARCH